STM2457

HY-134836		
2499663-01	-1	
$C_{25}H_{28}N_6O_2$		
444.53		
Apoptosis		
Apoptosis		
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month
	2499663-01 C ₂₅ H ₂₈ N ₆ O ₂ 444.53 Apoptosis Apoptosis Powder	2499663-01-1 C ₂₅ H ₂₈ N ₆ O ₂ 444.53 Apoptosis Apoptosis Powder -20°C 4°C In solvent -80°C

®

MedChemExpress

SOLVENT & SOLUBILITY

		Mass Solvent Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	2.2496 mL	11.2478 mL	22.4957 mL	
	5 mM 10 mM	5 mM	0.4499 mL	2.2496 mL	4.4991 mL	
		0.2250 mL	1.1248 mL	2.2496 mL		
	Please refer to the sc	lubility information to select the ap	propriate solvent.			
In Vivo	1. Add each solvent one by one: 20% HP-β-CD in saline Solubility: 5 mg/mL (11.25 mM); Clear solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution					
	 Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution 					

BIOLOGICAL ACTIVITY					
Description	STM2457 is a first-in-class, highly potent, selective and orally active METTL3 inhibitor with an IC ₅₀ of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML) ^{[1][2]} .				
In Vitro	STM2457 (Compound 72) inhibits MOLM13 cells proliferation with an IC ₅₀ of 8.699 μ M ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

н'n-

CUSTOMER VALIDATION

- Nat Biotechnol. 2024 Jan 2.
- Nat Biotechnol. 2023 Mar;41(3):355-366.
- Gastroenterology. 2022 Jun 11;S0016-5085(22)00629-1.
- Cancer Commun (Lond). 2022 Mar 9.
- Cell Rep Med. 2023 Aug 15;4(8):101144.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wesley Peter Blackaby, et al. Mettl3 inhibitory compounds. WO2020201773A1.

[2]. Eliza Yankova, et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021 Apr 26.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA